Preoperative Dual Immunotherapy Shows Promise in High-Risk Early HER2-Negative Breast Cancer
WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before ...
WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before ...
Advanced triple-negative breast cancer may benefit from an unexpected combination: stereotactic ablative body radiotherapy (SABR) delivered either in a single ...
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
A groundbreaking study has unveiled new insights into the complex biology of cancer-associated fibroblasts (CAFs) within triple-negative breast cancer (TNBC), ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking study poised to reshape the therapeutic landscape of aggressive breast cancers, researchers have uncovered a novel metabolic ...
In a groundbreaking study published in the Journal of Translational Medicine, researchers Li, Chen, and Wang lead an exploration into ...
Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in oncology due to its aggressive nature and its ...
In a groundbreaking study unveiled recently, researchers have illuminated the complex metabolic dependencies underpinning triple-negative breast cancer (TNBC), highlighting a ...
Triple-negative breast cancer (TNBC) is notorious for its aggressive nature and resistance to conventional therapies, creating an urgent need for ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine